Literature DB >> 4060097

Mast cell and histamine content of human bronchoalveolar lavage fluid.

R M Agius, R C Godfrey, S T Holgate.   

Abstract

Bronchoalveolar lavage was performed in 97 patients including control patients with bronchial carcinoma (24) and patients with sarcoidosis (20), cryptogenic fibrosing alveolitis (9), and asthma (4), and others. Cytocentrifuged slides were stained by two methods: May-Grünwald Giemsa and toluidine blue. In the last 32 subjects the bronchoalveolar lavage fluid was separated into supernatant and cell pellet for the subsequent assay of the performed mast cell mediator, histamine. Comparison of the two methods of staining showed a bias towards toluidine blue. Controls had a differential mean (SE) mast cell count of 0.07% (0.01%). Higher counts were noted in cryptogenic fibrosing alveolitis--0.61% (0.15%) (p less than 0.001)--and in sarcoidosis--0.14% (0.02%) (p less than 0.05). There was a strong correlation between absolute mast cell counts and cell lysate histamine concentration (r = 0.78, p less than 0.001). Less strong, significant, correlations between supernatant histamine concentration and absolute mast cell counts (r = 0.48, p less than 0.01) or cell lysate histamine concentration (r = 0.72, p less than 0.01) were also found. Derived mean values of histamine per mast cell ranged from 3.7 to 10.9 picograms. The mean histamine content of lavage fluid supernatant as a percentage of the total lavage fluid histamine was 24.9% (3.3%). The possible clinical significance of these findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4060097      PMCID: PMC460180          DOI: 10.1136/thx.40.10.760

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Mast cells in rat gastrointestinal mucosa. 2. Dye-binding and metachromatic properties.

Authors:  L Enerbäck
Journal:  Acta Pathol Microbiol Scand       Date:  1966

2.  Inflammatory mediators and mechanisms of release from purified human basophils and mast cells.

Authors:  R P Schleimer; D W MacGlashan; S P Peters; R Naclerio; D Proud; N F Adkinson; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1984-10       Impact factor: 10.793

3.  Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats.

Authors:  T Goto; D Befus; R Low; J Bienenstock
Journal:  Am Rev Respir Dis       Date:  1984-11

4.  Accurate quantification of cells recovered by bronchoalveolar lavage.

Authors:  C Saltini; A J Hance; V J Ferrans; F Basset; P B Bitterman; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1984-10

5.  Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features.

Authors:  P L Haslam; C W Turton; B Heard; A Lukoszek; J V Collins; A J Salsbury; M Turner-Warwick
Journal:  Thorax       Date:  1980-01       Impact factor: 9.139

6.  Effect of glycaemic control and duration of disease on overnight albumin excretion in diabetic children.

Authors:  D J Rowe; M Hayward; H Bagga; P Betts
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-13

7.  Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders.

Authors:  O Kawanami; V J Ferrans; J D Fulmer; R G Crystal
Journal:  Lab Invest       Date:  1979-06       Impact factor: 5.662

8.  Bronchoalveolar lavage in the diagnosis of diffuse pulmonary shadowing.

Authors:  P R Studdy; R M Rudd; A R Gellert; S Uthayakumar; G Sinha; D M Geddes
Journal:  Br J Dis Chest       Date:  1984-01

9.  Heterogeneity of human mast cells.

Authors:  E S Schulman; A Kagey-Sobotka; D W MacGlashan; N F Adkinson; S P Peters; R P Schleimer; L M Lichtenstein
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

10.  Living histamine-containing cells from the bronchial lumens of humans. Description and comparison of histamine content with cells of rhesus monkeys.

Authors:  R Patterson; J M McKenna; I M Suszko; N H Solliday; J J Pruzansky; M Roberts; T J Kehoe
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

View more
  10 in total

Review 1.  Staub and Bovet Award 1989 lecture. Some aspects of mast cell subtypes from human lung tissue.

Authors:  F J van Overveld
Journal:  Agents Actions       Date:  1990-04

2.  Elevated histamine content of lung lavage in human asbestosis.

Authors:  R Bégin; Y Desmarais; M Martel; R Boileau; Y Vézina; S Massé
Journal:  Lung       Date:  1986       Impact factor: 2.584

3.  Release of elastase from purified human lung mast cells and basophils. Identification as a Hageman factor cleaving enzyme.

Authors:  H L Meier; E S Schulman; L W Heck; D MacGlashan; H H Newball; A P Kaplan
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

4.  Bronchoalveolar mast cells in extrinsic asthma.

Authors:  A J Wardlaw; A B Kay
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-09

Review 5.  Aspects of histamine metabolism.

Authors:  J P Green; G D Prell; J K Khandelwal; P Blandina
Journal:  Agents Actions       Date:  1987-10

6.  The pathophysiology of bronchial asthma and targets for its drug treatment.

Authors:  S T Holgate
Journal:  Agents Actions       Date:  1986-06

7.  Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis.

Authors:  K A Boomars; S S Wagenaar; P G Mulder; H van Velzen-Blad; J M van den Bosch
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

8.  Role of mast cells in the pathogenesis of hypersensitivity pneumonitis.

Authors:  P Soler; S Nioche; D Valeyre; F Basset; J Benveniste; C Burtin; J P Battesti; R Georges; A J Hance
Journal:  Thorax       Date:  1987-08       Impact factor: 9.139

9.  Cutaneous response to intradermal histamine in lung cancer.

Authors:  G Cavigioli; B Mastropasqua; A Pelucchi; P Mazza; L Marazzini
Journal:  Agents Actions       Date:  1991-11

10.  The reproducibility and effect on non-specific airway responsiveness of inhaled prostaglandin D2 and leukotriene D4 in asthmatic subjects.

Authors:  R Wood-Baker; G I Town; B Benning; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.